XTX Topco’s Carisma Therapeutics CARM Stock Holding History

XTX Topco’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40,097	Closed	-$1.72K	–	3879
2025 Q4	$1.72K	Buy	+40,097	New	+$10K	﹤0.01%	3248
2024 Q2	–	Sell	-12,540	Closed	-$28.5K	–	1912
2024 Q1	$28.5K	Buy	+12,540	New	+$30.1K	﹤0.01%	1559
2022 Q1	–	Sell	-884	Closed	-$14K	–	694
2021 Q4	$14K	Buy	+884	New	+$17.8K	0.01%	638
2021 Q3	–	Sell	-800	Closed	-$74K	–	721
2021 Q2	$74K	Buy	+800	New	+$51K	0.02%	690

Other funds holding CARM

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

GSEP

Golden State Equity Partners South Coast Metro, California $1.32B AUM 23.87% 1-Year Est. Return

XTX Topco's CARM Position: Q1 2026 in Review

XTX Topco sold out of Carisma Therapeutics (CARM) in Q1 2026, closing a stake of 40,097 shares — an estimated $1.72K sold.

XTX Topco first reported a position in CARM in Q2 2021 and held it in 4 quarters. The position peaked at $74K in Q2 2021. 3 funds tracked by Wall St. Rank hold CARM as of Q1 2026.

XTX Topco reported no remaining Carisma Therapeutics position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 40,097 Carisma Therapeutics shares in Q1 2026, an estimated $1.72K.
XTX Topco first reported a position in Carisma Therapeutics in Q2 2021 and held it in 4 quarters.
XTX Topco's Carisma Therapeutics position peaked at $74K in Q2 2021.
3 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.